Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. develops oncology immunotherapies as a clinical-stage biotechnology company with American depositary shares traded under PPBT. Its recurring updates center on CAPTN-3, a platform of capped or masked tri-specific antibodies designed to target tumor-associated antigens while engaging both T cells and NK cells in the tumor microenvironment.
Company news commonly covers preclinical data, toxicology and manufacturing work for IM1240, the 5T4-targeting lead CAPTN-3 antibody, and IM1305, the TROP2-targeting development candidate. Other recurring themes include oncology research collaborations, scientific advisory activity, financial results, ADR and capital-structure actions, Nasdaq listing compliance, and governance updates.
Purple Biotech announced the closing of an exercise of existing warrants, resulting in gross proceeds of approximately $2 million. The company issued new unregistered Series A-1 and A-2 warrants in consideration for the exercise of the existing ones.
The new warrants are exercisable immediately, with varying terms of twenty-four months to five years, and an exercise price of $0.40 per ADS. Net proceeds will fund oncology therapeutic candidates' development and general corporate purposes.
Purple Biotech announced the exercise of existing warrants, generating approximately $2 million in gross proceeds. The exercised warrants, initially priced between $1.25 to $20.00 per ADS, were reduced to $0.36 per ADS. This exercise involves 5,633,509 ADSs. In return, Purple Biotech will issue new Series A-1 and A-2 warrants, allowing the purchase of an additional 4,979,383 and 6,287,635 ADSs at $0.40 per ADS. The A-1 warrants have a five-year term, and the A-2 warrants have a 24-month term. The proceeds will fund oncology therapeutic development and general corporate purposes. The offering is compliant with regulatory standards, closing expected by July 2, 2024, with H.C. Wainwright & Co. as the exclusive placement agent.
Purple Biotech announced positive interim results from its Phase 2 pancreatic cancer study with CM24, nivolumab, and standard chemotherapy. The data, presented at the 2024 ASCO meeting, showed a 26% reduction in death risk and a 28% reduction in progression or death risk in the CM24 combination arm versus standard chemotherapy alone. Median overall survival (OS) was extended by 2.1 months, and median progression-free survival (PFS) was extended by 1.9 months. Additionally, the study found higher objective response rates (25% vs 7%) and disease control rates (63% vs 40%) in the combination arm. Baseline serum myeloperoxidase (MPO) levels may predict survival improvement. Further results are expected in the second half of 2024, with a KOL event scheduled for July 11, 2024.
Purple Biotech announced interim data from its Phase 2 study of CM24 in combination with nivolumab and standard-of-care (SoC) chemotherapy for second-line metastatic pancreatic cancer (PDAC) at ASCO 2024.
The results show a 26% reduction in the risk of death and a 28% reduction in risk of progression or death. Patients treated with CM24+nivolumab+SoC had a median overall survival of 7.72 months compared to 5.62 months with SoC alone.
Additionally, the combination therapy resulted in a 1.9-month improvement in median progression-free survival. The objective response rate (ORR) and disease control rate (DCR) were also higher in the experimental arm (25% and 63%, respectively) compared to SoC (7% and 40%).
The study enrolled 63 patients across 18 centers in the U.S., Spain, and Israel. The investigational therapy was well-tolerated with manageable side effects. Topline final data is expected by the end of 2024.
Purple Biotech announced its Q1 2024 financial results. Key highlights include interim Phase 2 data for CM24 in pancreatic cancer to be presented at ASCO 2024, suggesting a reduced risk of disease progression and death. Topline data expected in Q4 2024. Positive efficacy data for NT219 in head and neck cancer were presented at ESMO-TAT 2024, with a Phase 2 trial planned for 2024. The company reported a net loss of $3.8 million, down from $4.9 million in Q1 2023, and operating losses decreased to $4.5 million. Purple Biotech's cash position stands at $10.8 million, providing a runway into Q1 2025. Sales, general, and administrative expenses decreased by 37.5% to $1 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.